Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $9.00 Average PT from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned an average rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $9.00.

A number of brokerages have weighed in on INO. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Citigroup reiterated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, November 4th. Piper Sandler restated an “overweight” rating and issued a $6.00 price target (up previously from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.60 on Wednesday. The company has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $2.05. The company has a market cap of $106.77 million, a PE ratio of -0.62 and a beta of 1.62. Inovio Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.07. On average, analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. MCF Advisors LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth $26,000. SG Americas Securities LLC purchased a new stake in Inovio Pharmaceuticals during the third quarter valued at about $27,000. Stephens Inc. AR acquired a new stake in Inovio Pharmaceuticals during the third quarter worth about $32,000. Focus Partners Wealth purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Raymond James Financial Inc. lifted its stake in shares of Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.